Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

lupus

- PMLiVE

BMS partners with Simcere to market arthritis drug Orencia SC in China

Builds on existing cancer/ cholesterol alliance between pharma companies

- PMLiVE

BMS’ Orencia matches Humira in arthritis study

Data should help drug establish itself against AbbVie's market-leading RA medicine

- PMLiVE

GSK buys rights to MorphoSys’ arthritis antibody

Pharma company will pay up €445m to develop and commercialise MOR103

- PMLiVE

AstraZeneca drops arthritis candidate fostamatinib

Hands rights back to Rigel after late-stage trial disappointment

- PMLiVE

FDA refuses to back Gilead’s two HIV drugs

Agency questions quality of testing procedures for elvitegravir and cobicistat

- PMLiVE

EMA refuses to back Pfizer’s Xeljanz in rheumatoid arthritis

Surprise after approvals in US and Japan

- PMLiVE

Quality Standards – are we making the most of them?

As the UK health service enters a new chapter, NICE begins developing best practice guidelines

- PMLiVE

EU recommendations for Gilead, Ariad and Baxter drugs

EMA backs use of HyQvia, Iclusig and Stribild

- PMLiVE

Gilead recalls Vistide due to foreign particles

Affected batch of AIDS symptom treatment sold in the US, Europe and Canada

- PMLiVE

Lilly abandons tabalumab for rheumatoid arthritis

Decision based on lack of efficacy in late-stage trials

- PMLiVE

Gilead $1bn antibody deal with MacroGenics

Joins Boehringer and Servier in use of US biotech’s DART technology

UCB launches arthritis exercise programme in the UK

Scheme was piloted at two NHS Trusts during 2011

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links